CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/II....
Phase 2, Phase 3
Paris, France and 61 other locations
This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent glioma...
Phase 2
Paris, France and 80 other locations
are also impermeable to the passage of therapeutic molecules from the blood to the brain. The development of effective treatments against glioblastoma...
Phase 3
Paris, France and 22 other locations
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM...
Paris, France and 132 other locations
(TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), biliary tract cancers (BTC), or pancreatic can...
Phase 2
Villejuif, Val-de-Marne, France and 87 other locations
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an...
Phase 1, Phase 2
Villejuif, France and 18 other locations
This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard firs...
Phase 2
Paris, France and 47 other locations
To assess:* efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification...
Phase 2
Paris, France and 90 other locations
Clinical trials
Research sites
Resources
Legal